CONCLUSIONS:
The combination of veliparib with metronomic cyclophosphamide is well tolerated and shows promising activity in a subset of patients with BRCA mutations. A phase II trial of the combination compared to single-agent cyclophosphamide is ongoing in BRCA-positive
ovarian cancer, triple-negative breast
cancer, and low-grade lymphoma.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.